Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga] Ga-HER2 sdAb PET/CT to predict pCR after neoadjuvant chemotherapy in HER2-positive early breast cancer
2025-523286-23-00Phase 2Authorised
- Sponsor
- Centre Henri Becquerel
- Start
- Jan 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-ABS011 in breast cancer, sponsored by Centre Henri Becquerel. Primary endpoint: Primary endpoint: Concordance between PET/CT response and pathological complete response. Planned start Jan 2026; status: authorised.
02
Drugs
68Ga-ABS011
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-523286-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523286-23-00.